In addition to CCL2, CCL22, and IL-10, TAM-associated markers CCL5 and SPP1 (secreted phosphosprotein 1, also known as osteopontin, OPN) are promising targets for novel cancer immunotherapy [34,35]. The gene discussed is CCL5; the disease is cancer.